Reported Earnings • Jun 01
Full year 2026 earnings released: EPS: ₹2.76 (vs ₹0.046 in FY 2025) Full year 2026 results: EPS: ₹2.76 (up from ₹0.046 in FY 2025). Revenue: ₹5.74b (up ₹5.73b from FY 2025). Net income: ₹15.1m (up ₹14.8m from FY 2025). Profit margin: 0.3% (down from 5.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 112% per year whereas the company’s share price has increased by 111% per year. Announcement • May 23
Checkpoint Trends Limited to Report Q4, 2026 Results on May 30, 2026 Checkpoint Trends Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026 Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₹44.44, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 756% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹39.28, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 33x in the Healthcare industry in India. Total returns to shareholders of 130% over the past year. Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹52.16, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 36x in the Healthcare industry in India. Total returns to shareholders of 1,005% over the past three years. Announcement • Mar 18
Checkpoint Trends Limited Board Resignations, Effective March 18, 2026 Checkpoint Trends Limited announced that based on the recommendations of Nomination and Remuneration Committee meeting held on March 18, 2026 and the Board of Directors of the Company at its meeting held on March 18, 2026 inter alia, considered and approved the following: Resignation of Ms. Bhawna Saunkhiya (DIN: 10683032) as Non- Executive and Independent Director of the Company due to pre-occupation and other personal commitments. Date of Resignation: March 18, 2026. Resignation of Mr. Saurabh (DIN: 10790325) as Non- Executive and Independent Director of the Company. due to pre-occupation and other personal commitments. Date of Resignation: March 18, 2026. New Risk • Mar 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹246.5m market cap, or US$2.67m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹85.00, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 38x in the Healthcare industry in India. Total returns to shareholders of 1,701% over the past three years. Reported Earnings • Jan 29
Third quarter 2026 earnings released Third quarter 2026 results: EPS: ₹1.05. Revenue: ₹1.74b (up ₹1.74b from 3Q 2025). Net income: ₹5.75m (up ₹5.93m from 3Q 2025). Profit margin: 0.3% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has increased by 200% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 19
Checkpoint Trends Limited to Report Q3, 2026 Results on Jan 28, 2026 Checkpoint Trends Limited announced that they will report Q3, 2026 results on Jan 28, 2026 Valuation Update With 7 Day Price Move • Jan 01
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹120, the stock trades at a trailing P/E ratio of 45.1x. Average trailing P/E is 41x in the Healthcare industry in India. Total returns to shareholders of 2,566% over the past three years. Buy Or Sell Opportunity • Dec 30
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 118% to ₹109. The fair value is estimated to be ₹90.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 151% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Dec 05
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 189% to ₹110. The fair value is estimated to be ₹90.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 151% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹2.42 (vs ₹0.08 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹2.42 (up from ₹0.08 loss in 2Q 2025). Revenue: ₹1.09b (up ₹1.09b from 2Q 2025). Net income: ₹13.2m (up ₹13.7m from 2Q 2025). Profit margin: 1.2% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has increased by 170% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 04
Checkpoint Trends Limited to Report First Half, 2026 Results on Nov 12, 2025 Checkpoint Trends Limited announced that they will report first half, 2026 results on Nov 12, 2025 Announcement • Sep 11
Checkpoint Trends Limited announced that it expects to receive funding from Rajvansh Electricals Private Limited, Golden Bio Energy Limited and other investors. Checkpoint Trends Limited announced a private placement to issue 51,436,781 Convertible warrants on September 10, 2025. The transaction involves participation of Rajvansh Electricals Private Limited for 9,074,410 warrant, Golden Bio Energy Limited for 9,074,410 warrant, Recoll Projects Private Limited for 9,074,410 warrant , Pradeep Kumar for 15,124,017 warrant and other investors. Each Warrant will be convertible into, or exchangeable for 1 (one) fully paid-up equity share within 18 (eighteen) months from the date of allotment of the Warrants. The transaction is approved by board of director and still subject to shareholder approval. Announcement • Aug 29
Checkpoint Trends Limited, Annual General Meeting, Sep 29, 2025 Checkpoint Trends Limited, Annual General Meeting, Sep 29, 2025, at 16:00 Indian Standard Time. Reported Earnings • Aug 07
First quarter 2026 earnings released: EPS: ₹0.16 (vs ₹0.05 in 1Q 2025) First quarter 2026 results: EPS: ₹0.16 (up from ₹0.05 in 1Q 2025). Revenue: ₹117.1m (up ₹116.1m from 1Q 2025). Net income: ₹889.0k (up 259% from 1Q 2025). Profit margin: 0.8% (down from 25% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 124% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 29
Checkpoint Trends Limited to Report Q2, 2025 Results on Aug 06, 2025 Checkpoint Trends Limited announced that they will report Q2, 2025 results on Aug 06, 2025 Reported Earnings • May 30
Full year 2025 earnings released: EPS: ₹0.05 (vs ₹0.055 in FY 2024) Full year 2025 results: EPS: ₹0.05 (down from ₹0.055 in FY 2024). Revenue: ₹5.01m (down 56% from FY 2024). Net income: ₹254.0k (down 16% from FY 2024). Profit margin: 5.1% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 14
Checkpoint Trends Limited to Report Q4, 2025 Results on May 28, 2025 Checkpoint Trends Limited announced that they will report Q4, 2025 results on May 28, 2025 New Risk • Mar 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$91k). Market cap is less than US$10m (₹90.0m market cap, or US$1.03m). New Risk • Feb 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$90k). Market cap is less than US$10m (₹63.3m market cap, or US$723.2k). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Announcement • Feb 03
Checkpoint Trends Limited to Report Q3, 2025 Results on Feb 12, 2025 Checkpoint Trends Limited announced that they will report Q3, 2025 results on Feb 12, 2025 New Risk • Nov 12
New major risk - Revenue and earnings growth Earnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (₹7.9m revenue, or US$94k). Market cap is less than US$10m (₹73.8m market cap, or US$874.6k). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Announcement • Nov 05
Checkpoint Trends Limited to Report Q2, 2025 Results on Nov 11, 2024 Checkpoint Trends Limited announced that they will report Q2, 2025 results on Nov 11, 2024 Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹9.75, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 48x in the Healthcare industry in India. Total returns to shareholders of 153% over the past three years. Announcement • Sep 16
Checkpoint Trends Limited Approves Appointment of Artee Sahu as Company Secretary and Compliance Officer Checkpoint Trends Limited announced that, the board of directors of the company at its meeting held on September 16, 2024 inter alia, has considered and approved the appointment of Ms. Artee Sahu as company secretary and compliance officer of the company. Date of Appointment is September 16, 2024. Ms. Artee Sahu is a qualified company secretary. She is expert in companies Act 2013 and SEBI (LODR) 2015. Announcement • Sep 06
Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024 Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time. New Risk • Sep 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹10m revenue, or US$123k). Market cap is less than US$10m (₹43.9m market cap, or US$522.2k). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Valuation Update With 7 Day Price Move • Sep 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹7.64, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 49x in the Healthcare industry in India. Total returns to shareholders of 40% over the past year. Reported Earnings • Aug 15
First quarter 2025 earnings released First quarter 2025 results: EPS: ₹0.05. Revenue: ₹1.00m (down 50% from 1Q 2024). Net income: ₹248.0k (up ₹788.0k from 1Q 2024). Profit margin: 25% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Announcement • Aug 06
Checkpoint Trends Limited to Report Q1, 2025 Results on Aug 13, 2024 Checkpoint Trends Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹8.03, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 107% over the past three years. Announcement • May 26
Checkpoint Trends Limited Announces Cessation of Sunil Khandalwal as Managing Director, with Effect from May 27, 2024 Checkpoint Trends Limited announced that at the board meeting held on May 25, 2024, the company approved the cessation of Mr. Sunil Khandalwal as Managing Director of the Company due to the expiry of tenure and not being reappointed. Date of Cessation- With effect from May 27, 2024. Announcement • May 17
Checkpoint Trends Limited to Report Q4, 2024 Results on May 25, 2024 Checkpoint Trends Limited announced that they will report Q4, 2024 results at 3:30 PM, Indian Standard Time on May 25, 2024 Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non Executive Independent Director Harish Surve was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹9.22, the stock trades at a trailing P/E ratio of 32x. Average trailing P/E is 38x in the Healthcare industry in India. Total returns to shareholders of 281% over the past three years. Reported Earnings • Feb 08
Third quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.004 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.10 (up from ₹0.004 in 3Q 2023). Revenue: ₹1.71m (down 19% from 3Q 2023). Net income: ₹570.0k (up ₹548.0k from 3Q 2023). Profit margin: 33% (up from 1.0% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹9.27, the stock trades at a trailing P/E ratio of 49.4x. Average trailing P/E is 47x in the Healthcare industry in India. Total returns to shareholders of 331% over the past three years. Announcement • Jan 29
Checkpoint Trends Limited to Report Q3, 2024 Results on Feb 07, 2024 Checkpoint Trends Limited announced that they will report Q3, 2024 results on Feb 07, 2024 Announcement • Jan 25
Checkpoint Trends Limited Announces Resignation of Komal Behl, Company Secretary Checkpoint Trends Limited announced that Ms. Komal Behl, Company Secretary of the Company has tendered her resignation with effect from January 24, 2024 (at the end of working hours) due to personal reason. Valuation Update With 7 Day Price Move • Jan 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹4.87, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 41x in the Healthcare industry in India. Total returns to shareholders of 106% over the past three years. Reported Earnings • Nov 09
Second quarter 2024 earnings released: EPS: ₹0.47 (vs ₹0.02 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.47 (up from ₹0.02 in 2Q 2023). Revenue: ₹2.90m (down 19% from 2Q 2023). Net income: ₹2.59m (up ₹2.49m from 2Q 2023). Profit margin: 89% (up from 2.6% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 28
Checkpoint Trends Limited to Report First Half, 2024 Results on Nov 07, 2023 Checkpoint Trends Limited announced that they will report first half, 2024 results on Nov 07, 2023 Announcement • Aug 31
Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023 Checkpoint Trends Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Reported Earnings • Aug 17
First quarter 2024 earnings released First quarter 2024 results: Revenue: ₹2.00m (down 61% from 1Q 2023). Net loss: ₹540.0k (down 478% from profit in 1Q 2023). Announcement • Aug 03
Checkpoint Trends Limited to Report Q1, 2024 Results on Aug 11, 2023 Checkpoint Trends Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Reported Earnings • May 28
Full year 2023 earnings released Full year 2023 results: Revenue: ₹11.6m (down 42% from FY 2022). Net loss: ₹785.0k (loss widened 115% from FY 2022). Announcement • May 19
Checkpoint Trends Limited to Report Q4, 2023 Results on May 26, 2023 Checkpoint Trends Limited announced that they will report Q4, 2023 results on May 26, 2023 Reported Earnings • Feb 15
Third quarter 2023 earnings released Third quarter 2023 results: EPS: ₹0.004. Revenue: ₹2.11m (down 51% from 3Q 2022). Net income: ₹22.0k (up ₹430.0k from 3Q 2022). Profit margin: 1.0% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance. Announcement • Jan 31
Checkpoint Trends Limited to Report Q3, 2023 Results on Feb 13, 2023 Checkpoint Trends Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Announcement • Dec 08
Checkpoint Trends Limited Announces Company Secretary Changes Checkpoint Trends Limited announced that Ms. Ritu Chattani, Company Secretary of the Company has tendered her resignation with immediate effect for better prospectus. Ms. Komal Behl, has been appointed as the CompanySecretary and Compliance Officer of the Company with immediate effect. Ms. Komal Behl is a qualified Company Secretary. She is having an experience of over five years in the secretarial field. She has worked as a professional prior to joining Company. Ms. Komal Behl is not related to any of the directors of the company. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.03 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.02 (down from ₹0.03 in 2Q 2022). Revenue: ₹3.60m (up 39% from 2Q 2022). Net income: ₹93.0k (down 34% from 2Q 2022). Profit margin: 2.6% (down from 5.4% in 2Q 2022). The decrease in margin was driven by higher expenses. Announcement • Oct 30
Checkpoint Trends Limited to Report First Half, 2023 Results on Nov 10, 2022 Checkpoint Trends Limited announced that they will report first half, 2023 results on Nov 10, 2022 Announcement • Aug 12
Rubra Medicaments Limited, Annual General Meeting, Sep 30, 2022 Rubra Medicaments Limited, Annual General Meeting, Sep 30, 2022, at 11:00 Indian Standard Time. Announcement • Aug 03
Rubra Medicaments Limited to Report Q1, 2023 Results on Aug 11, 2022 Rubra Medicaments Limited announced that they will report Q1, 2023 results on Aug 11, 2022 Announcement • May 14
Rubra Medicaments Limited to Report Fiscal Year 2022 Results on May 25, 2022 Rubra Medicaments Limited announced that they will report fiscal year 2022 results on May 25, 2022 Announcement • Feb 02
Rubra Medicaments Limited to Report Q3, 2022 Results on Feb 11, 2022 Rubra Medicaments Limited announced that they will report Q3, 2022 results on Feb 11, 2022 Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improved over the past week After last week's 15% share price gain to ₹3.00, the stock trades at a trailing P/E ratio of 61.4x. Average trailing P/E is 29x in the Healthcare industry in India. Total returns to shareholders of 43% over the past three years. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹2.71, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 36x in the Healthcare industry in India. Total returns to shareholders of 27% over the past three years. Is New 90 Day High Low • Feb 17
New 90-day low: ₹1.87 The company is down 12% from its price of ₹2.13 on 19 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 23% over the same period. Reported Earnings • Feb 14
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.00m (down 20% from 3Q 2020). Net income: ₹11.0k (down 94% from 3Q 2020). Profit margin: 1.1% (down from 15% in 3Q 2020). Announcement • Feb 01
Rubra Medicaments Limited to Report Q3, 2021 Results on Feb 12, 2021 Rubra Medicaments Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Dec 02
New 90-day high: ₹2.22 The company is up 14% from its price of ₹1.95 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 30% over the same period. Valuation Update With 7 Day Price Move • Nov 04
Market bids up stock over the past week After last week's 20% share price gain to ₹2.16, the stock is trading at a trailing P/E ratio of 37.4x, up from the previous P/E ratio of 31.2x. This compares to an average P/E of 35x in the Healthcare industry in India. Total return to shareholders over the past three years is a loss of 61%. Is New 90 Day High Low • Oct 22
New 90-day low: ₹1.64 The company is down 22% from its price of ₹2.09 on 24 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 21% over the same period. Announcement • Sep 22
Rubra Medicaments Limited Announces Appointment of Ms. Ritu Chhatani as Company Secretary and Compliance Officer Rubra Medicaments Limited announced that Ms. Ritu Chhatani has been appointed as the Company Secretary and Compliance Officer of the Company with effect from September 21, 2020. Ms. Ritu Chhatani is a qualified Company Secretary having an experience of over four years in the secretarial field. Announcement • Sep 14
Rubra Medicaments Limited Announces the Resignation of Manish Gandhi from the Post of Director Rubra Medicaments Limited announced that the Board of Directors has accepted the Resignation of Mr. Manish Gandhi from the post of Director of the Company with effect from September 12, 2020 due to his preoccupancy in other business. 
